Author(s):
Bhagyashree Arun Patil, Sanjay Surana, Atul Shirkhedkar
Email(s):
bhagyashreekhadse30@gmail.com , sjsurana@yahoo.com , shirkhedkar@gmail.com
DOI:
10.52711/0974-360X.2025.00554 
Address:
Bhagyashree Arun Patil, Sanjay Surana, Atul Shirkhedkar
R.C. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Maharashtra, 425405 India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 8,
Year - 2025
ABSTRACT:
The objective of this research was to increase the solubility of Antiretroviral Dolutegravir sodium (DGS), drug by utilizing co-crystallization technique as well formulating Suspension of Dolutegravir sodium cocrystals to enhance the therapeutic effectiveness. Dolutegravir Sodium (DGS) and Salicylic acid cocrystal were created in 1:1 ratio utilizing ethanol as solvent-by-solvent evaporation technique. Developed Cocrystals of Dolutegravir Sodium (DGS) and Salicylic acid assessed for preliminary characterization by utilizing PXRD, DCS, FTIR and SEM. Suspension that contained DGS cocrystals characterized for Dissolution rate, Drug content, Flow rate and Stability study. The findings indicated that the prepared suspension exhibited satisfactory characteristics and remained stable under the testing conditions. In vivo results demonstrate that the tested formulation exhibit quicker absorption compared to the formulation used as control. Hence it can be inferred that Suspension composed of Dolutegravir sodium (DGS) cocrystals shows improved therapeutic performance.
Cite this article:
Bhagyashree Arun Patil, Sanjay Surana, Atul Shirkhedkar. Fabrication of Dolutegravir Sodium Cocrystals: Characterization, In vitro, In vivo Evaluation of Cocrystal Suspension Formulation. Research Journal Pharmacy and Technology. 2025;18(8):3857-4. doi: 10.52711/0974-360X.2025.00554
Cite(Electronic):
Bhagyashree Arun Patil, Sanjay Surana, Atul Shirkhedkar. Fabrication of Dolutegravir Sodium Cocrystals: Characterization, In vitro, In vivo Evaluation of Cocrystal Suspension Formulation. Research Journal Pharmacy and Technology. 2025;18(8):3857-4. doi: 10.52711/0974-360X.2025.00554 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-8-57
REFERENCES:
1. Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014; 9(6). doi:10.1016/j.ajps.2014.05.005
2. Sevukarajan M, Bachala T, Sodanapalli R, Nair R. Co-crystals: An emerging trend in pharmaceutical industry. Res J Pharm Technol. 2011; 4(6).
3. Jit T, Shil D, Kumari Dasgupta R, Mallick S, Mukherjee S. Cocrystal: A Review on the Design and Preparation of Pharmaceutical Cocrystals. Asian Journal of Research in Pharmaceutical Sciences. Published online 2023. doi:10.52711/2231-5659.2023.00050
4. Guo M, Sun X, Chen J, Cai T. Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications. Acta Pharm Sin B. 2021; 11(8). doi:10.1016/j.apsb.2021.03.030
5. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des. 2009; 9(6). doi:10.1021/cg900129f
6. Eesam S, Bhandaru JS, Naliganti C, Bobbala RK, Akkinepally RR. Solubility enhancement of carvedilol using drug–drug cocrystallization with hydrochlorothiazide. Futur J Pharm Sci. 2020; 6(1). doi:10.1186/s43094-020-00083-5
7. Lee MK. Liposomes for enhanced bioavailability of water-insoluble drugs: In vivo evidence and recent approaches. Pharmaceutics. 2020; 12(3). doi:10.3390/pharmaceutics12030264
8. Kumar R, Soni GC, Prajapati SK. Formulation development and evaluation of Telmisartan Nanoemulsion. International Journal of Research and Development in Pharmacy and Life Sciences. 2017; 06(04). doi:10.21276/ijrdpl.2278-0238.2017.6(4).2711-2719
9. Kumari L, Choudhari Y, Patel P, et al. Advancement in Solubilization Approaches: A Step towards Bioavailability Enhancement of Poorly Soluble Drugs. Life. 2023; 13(5). doi:10.3390/life13051099
10. Mikhall GW, Eadon H, Rogers P, et al. Microemulsion formulation increases cyclosporin bioavailability in cystic fibrosis. The Lancet. 1995; 346(8990). doi:10.1016/S0140-6736(95)91977-5
11. Mali SS, Killedar SG. To Enhance the Physicochemical Properties of Metoprolol Succinate By Co-Crystal Technique. Res J Pharm Technol. 2017; 10(11). doi:10.5958/0974-360X.2017.00683.7
12. Muddukrishna BS, Bhat K, Shenoy GG. Preparation and solid-state characterization of paclitaxel cocrystals. Res J Pharm Technol. 2014; 7(1).
13. Joshi R, Raje S, Akram W, Garud N. Particle engineering of fenofibrate for advanced drug delivery system. Futur J Pharm Sci. 2019; 5(1). doi:10.1186/s43094-019-0010-0
14. Sekhon BS. Pharmaceutical co-crystals - A review. Ars Pharmaceutica. 2009; 50(3). doi:10.3390/iocc_2020-07331
15. Thimmasetty J, Shashank NN, Abdul Raheem T, Shwetha SKK, Tanmoy G. Modafinil cocrystals for altered physicochemical properties. Res J Pharm Technol. 2021; 14(9). doi:10.52711/0974-360X.2021.00850
16. Thimmasetty J, Ghosh T, Nayak NS, Raheem A. Oral Bioavailability Enhancement of Paliperidone by the use of Cocrystalization and Precipitation Inhibition. J Pharm Innov. 2021; 16(1). doi:10.1007/s12247-020-09428-2
17. Duggirala NK, Perry ML, Almarsson Ö, Zaworotko MJ. Pharmaceutical cocrystals: Along the path to improved medicines. Chemical Communications. 2016; 52(4). doi:10.1039/c5cc08216a
18. Garg U, Azim Y. Challenges and opportunities of pharmaceutical cocrystals: A focused review on non-steroidal anti-inflammatory drugs. RSC Med Chem. 2021; 12(5). doi:10.1039/d0md00400f
19. Buddhadev SS, Garala KC. Pharmaceutical Cocrystals—A Review. In:; 2021. doi:10.3390/proceedings2020062014
20. Karimi-Jafari M, Padrela L, Walker GM, Croker DM. Creating cocrystals: A review of pharmaceutical cocrystal preparation routes and applications. Cryst Growth Des. 2018; 18(10). doi:10.1021/acs.cgd.8b00933
21. Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev. 2007; 59(7). doi:10.1016/j.addr.2007.05.011
22. Kumar Bandaru R, Rout SR, Kenguva G, et al. Recent Advances in Pharmaceutical Cocrystals: From Bench to Market. Front Pharmacol. 2021; 12. doi:10.3389/fphar.2021.780582
23. Bolla G, Sarma B, Nangia AK. Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs. Chem Rev. 2022; 122(13). doi:10.1021/acs.chemrev.1c00987
24. Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discov Today. 2008; 13(9-10). doi:10.1016/j.drudis.2008.03.004
25. Shan N, Perry ML, Weyna DR, Zaworotko MJ. Impact of pharmaceutical cocrystals: The effects on drug pharmacokinetics. Expert Opin Drug Metab Toxicol. 2014; 10(9). doi:10.1517/17425255.2014.942281
26. Kothule KU, Gidwani SK, Gide P. Improved Pharmacokinetic Parameters of Acyclovir in Rats. Res J Pharm Technol. 2015; (1). doi:10.5958/0974-360X.2015.00007.4
27. Gaddam M, Ravouru N. Pharmacokinetic and Pharmacodynamic studies of Omeprazole Co-crystals dry suspension. Res J Pharm Technol. 2022; 15(1). doi:10.52711/0974-360X.2022.00080
28. Dutt B, Choudhary M, Budhwar V. Enhancement of Stability profile of Aspirin through Cocrystallization Technique. Res J Pharm Technol. 2022; 15(2). doi:10.52711/0974-360X.2022.00128
29. Miroshnyk I, Mirza S, Sandler N. Pharmaceutical co-crystals - An opportunity for drug product enhancement. Expert Opin Drug Deliv. 2009; 6(4). doi:10.1517/17425240902828304
30. Sun CC. Cocrystallization for successful drug delivery. Expert Opin Drug Deliv. 2013; 10(2). doi:10.1517/17425247.2013.747508
31. Aitipamula S, Vangala VR, Chow PS, Tan RBH. Cocrystal hydrate of an antifungal drug, griseofulvin, with promising physicochemical properties. Cryst Growth Des. 2012; 2(12). doi:10.1021/cg3012124
32. Martha S, Nedanuri A, Kalavathi A, Vahini BS, Kumar MP, Soumya S. Design and in vitro characterization of dolutegravir sustained release matrix tablets. Int J Pharm Sci Rev Res. 2017;6(2).
33. T. Balkrishna, Y.Pavan Sai Kumar and et al. T.Balkrishna. International journal of research in pharmacy and chemistry. 2023; 13(1): 38-45.
34. Bagade OM, Kad DR, Bhargude DN, Bhosale DR, Kahane SK. Consequences and impose of solubility enhancement of poorly water soluble drugs. Res J Pharm Technol. 2014; 7(5).
35. Nawale RB, Deokate UA, Shahi SR, Lokhande PM. Formulation and characterization of efavirenz nanosuspension by QbD approach. Res J Pharm Technol. 2017; 10(9). doi:10.5958/0974-360X.2017.00525.X
36. Steed JW. The role of co-crystals in pharmaceutical design. Trends Pharmacol Sci. 2013; 34(3). doi:10.1016/j.tips.2012.12.003
37. Setyawan D, Sari R, Yusuf H, Primaharinastiti R. Preparation and characterization of artesunate - Nicotinamide cocrystal by solvent evaporation and slurry method. Asian Journal of Pharmaceutical and Clinical Research. 2014;7(SUPPL. 1).
38. Blagden N, Coles SJ, Berry DJ. Pharmaceutical co-crystals-are we there yet? CrystEngComm. 2014; 16(26). doi:10.1039/c4ce00127c
39. Vasantrao Patil S, Sahoo SK. Spherical Crystallization: A Method to Improve Tabletability.; 2009. www.rjptonline.org
40. Hilya NI, Agnes Nuniek W, Setyawan D, Hendradi E. Improvement of dissolution properties through acyclovir - Succinic acid cocrystal using solvent evaporation technique. International Journal of Drug Delivery Technology. 2017; 7(4). doi:10.25258/ijddt.v7i04.10653
41. Myz SA, Shakhtshneider TP, Fucke K, et al. Synthesis of co-crystals of meloxicam with carboxylic acids by grinding. Mendeleev Communications. 2009; 19(5). doi:10.1016/j.mencom.2009.09.014
42. Ribas MM, Sakata GSB, Santos AE, et al. Curcumin cocrystals using supercritical fluid technology. Journal of Supercritical Fluids. 2019; 152. doi:10.1016/j.supflu.2019.104564
43. Narala S, Nyavanandi D, Alzahrani A, Bandari S, Zhang F, Repka MA. Creation of Hydrochlorothiazide Pharmaceutical Cocrystals Via Hot-Melt Extrusion for Enhanced Solubility and Permeability. AAPS PharmSciTech. 2022; 23(1). doi:10.1208/s12249-021-02202-8
44. Sahoo S, Chakraborti CK, Behera PK, Mishra SC. Analytical characterization of mucoadhesive norfloxacin/ carbopol934 polymeric suspension. International Journal of Pharmacy and Technology. 2011; 3(3).
45. Sahoo S, Chakraborti CK, Behera PK, Mishra SC. Characterization of mucoadhesive Norfloxacin suspensions by Fourier Transform Infrared Spectroscopy. International Journal of Drug Development and Research. 2011; 3(4).
46. Khushboo M, Naik K, Vasanthi, et al. Formulation and evaluation of irbesartan nanosuspension for dissolution enhancement. Res J Pharm Technol. 2017; 10(9). doi:10.5958/0974-360X.2017.00540.6
47. Azam MG, Haider SS. Evaluation of dissolution behavior of paracetamol suspensions. Dhaka University Journal of Pharmaceutical Sciences. 2008; 7(1). doi:10.3329/dujps.v7i1.1218
48. A. Sabri L, A. Abdul-Rasool A, A. Shehab M. Formulation of Rifampicin Suspension. Iraqi Journal of Pharmaceutical Sciences (P-ISSN: 1683 - 3597, E-ISSN : 2521 - 3512). 2017; 15(2). doi:10.31351/vol15iss2pp1-7
49. da Silva AS, da Rosa Silva CE, Paula FR, da Silva FEB. Discriminative Dissolution Method for Benzoyl Metronidazole Oral Suspension. AAPS PharmSciTech. 2016; 17(3). doi:10.1208/s12249-015-0407-9
50. Mahajan SM, Baviskar DT. Formulation Development and Evaluation of Polyherbal Suspension of Some Medicinal Plants. Int J Curr Res Rev. 2021; 13(12). doi:10.31782/ijcrr.2021.131208
51. Nadaf SJ, Salunkhe SS, Kamble PM. Formulation and evaluation of ciprofloxacin suspension using natural suspending agent. International Journal of Pharma Sciences and Research. 2014; 5(03).
52. Bhagwat A, Pathan IB, Chishti NAH. Design and optimization of pellets formulation containing curcumin ascorbic acid co-amorphous mixture for ulcerative colitis management. Particulate Science and Technology. 2021; 39(7). doi:10.1080/02726351.2020.1848946
53. Aitipamula S, Wong ABH, Kanaujia P. Evaluating Suspension Formulations of Theophylline Cocrystals With Artificial Sweeteners. J Pharm Sci. 2018; 107(2). doi:10.1016/j.xphs.2017.09.013
54. Ahmed TA, El-Say KM, Mahmoud MF, Samy AM, Badawi AA. Miconazole nitrate oral disintegrating tablets: In vivo performance and stability study. AAPS PharmSciTech. 2012; 13(3). doi:10.1208/s12249-012-9798-z
55. Kasliwal N, Negi JS, Jugran V, Jain R. Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet. Arch Pharm Res. 2011; 34(10). doi:10.1007/s12272-011-1013-3
56. Hua Y, Wu YS, Zheng DY, et al. Enhanced dissolution and tabletability of lornoxicam by cocrystallization. Yaoxue Xuebao. 2022; 57(4). doi:10.16438/j.0513-4870.2021-1060
57. B. Rodriques P, G. Prajapati B. Design and development of dolutegravir sodium co-crystals loaded orodispersible tablet with improved dissolution behaviour. Indian Drugs. 2023; 60(03): 30-39. doi:10.53879/id.60.03.13278.